Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396353 | 0.87 | CHRM1 (0.59) | CHRM1LMNATOP1 | |
| SCHEMBL2397287 | 0.86 | HDAC1 (0.48) | CHRM1HDAC1HDAC6 | |
| SCHEMBL12310583 | 0.83 | HDAC1 (0.56) | CHRM1HDAC1HDAC6CSNK2A2CSNK2B | |
| SCHEMBL8010329 | 0.81 | HDAC1 (0.43) | CHRM1HDAC1HDAC6LMNACSNK2A2 | |
| SCHEMBL2397468 | 0.79 | CHRM1 (0.53) | CHRM1LMNATOP1 | |
| SCHEMBL15579849 | 0.78 | HDAC1 (0.42) | CHRM1HDAC1HDAC6LMNATOP1 | |
| SCHEMBL15579846 | 0.78 | CHRM1 (0.52) | CHRM1LMNATOP1 | |
| SCHEMBL2394809 | 0.77 | KDM4E (0.43) | HDAC1HDAC6LMNAGAA | |
| SCHEMBL8010272 | 0.77 | CHRM1 (0.51) | CHRM1LMNATOP1 | |
| SCHEMBL2393836 | 0.76 | CHRM1 (0.49) | CHRM1LMNATOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022215-B2 | Fused pyridone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022215-B2 | Fused pyridone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2009102588-A1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885HDAC1 1696/4885HDAC6 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.